1-2 of 2
for the GIMEMA CML Working Party
Close
Sort by
Journal Articles

Nilotinib for the frontline treatment of Ph + chronic myeloid leukemia

Clinical Trials & Observations
Gianantonio Rosti, Francesca Palandri, Fausto Castagnetti, Massimo Breccia, Luciano Levato, Gabriele Gugliotta, Adele Capucci, Michele Cedrone, Carmen Fava, Tamara Intermesoli, Giovanna Rege Cambrin, Fabio Stagno, Mario Tiribelli, Marilina Amabile, Simona Luatti, Angela Poerio, Simona Soverini, Nicoletta Testoni, Giovanni Martinelli, Giuliana Alimena, Fabrizio Pane, Giuseppe Saglio, Michele Baccarani, for the GIMEMA CML Working Party
Journal: Blood
Blood (2009) 114 (24): 4933–4938.
https://doi.org/10.1182/blood-2009-07-232595
Published: 2009
Journal Articles

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party

Clinical Trials & Observations
Fausto Castagnetti, Francesca Palandri, Marilina Amabile, Nicoletta Testoni, Simona Luatti, Simona Soverini, Ilaria Iacobucci, Massimo Breccia, Giovanna Rege Cambrin, Fabio Stagno, Giorgina Specchia, Piero Galieni, Franco Iuliano, Fabrizio Pane, Giuseppe Saglio, Giuliana Alimena, Giovanni Martinelli, Michele Baccarani, Gianantonio Rosti, for the GIMEMA CML Working Party
Journal: Blood
Blood (2009) 113 (15): 3428–3434.
https://doi.org/10.1182/blood-2007-08-103499
Published: 2009